Navigation Links
Telik Announces Fourth Quarter And 2012 Year End Financial Results And 2013 Financial Guidance
Date:3/15/2013

rome (MDS).  Orphan designation grants potential US market exclusivity to a drug for the treatment of a specified condition for a period of seven years following FDA marketing approval.  Additional potential benefits of orphan designation include development grants, tax credits related to clinical trial expenses, protocol development assistance and exemption from FDA user fees. 

Results of clinical trials with Telintra were reported in peer reviewed medical publications including:

  • "Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)," Raza, A., et al., Journal of Hematology & Oncology 2012, 5:18 doi:10.1186/1756-8722-5-18; 30 April 2012. Significant findings of the study included multilineage responses and good tolerability, supporting the further development of the Telintra and Revlimid® combination in MDS as well as in other hematologic malignancies where Revlimid is a standard of care.
  • "Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome," Galili, N. et al., Journal of Hematology & Oncology 2012, 5:20 doi:10.1186/1756-8722-5-20; 6 May 2012. A gene marker analysis was performed using RNA available from 30 patients enrolled in a Phase 2 Telintra clinical trial. Pathway analysis of the response profile revealed that the genes comprising the jun-N-terminal kinase/c-JUN molecular pathway, which is known to be influenced by Telintra, were under-expressed in responders and over-expressed in non-responders, providing additional support for the novel mechanism of action of Telintra and a potential basis for a companion diagnostic.
  • "Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, for Treatment of Patients with Myeloid Growth Factor-Resistant Idiopathic Chronic Neutropenia (ICN)," by '/>"/>

  • SOURCE Telik, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Telik Announces Third Quarter 2012 Financial Results
    2. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
    3. ULURU Inc. Announces Closing Of $440,000 Private Placement
    4. Cardica Announces Proposed Public Offering of Common Stock
    5. PAREXEL International Provides Update On Share Repurchase Program, Announces A New $50 Million Accelerated Share Repurchase Agreement And A New $50 Million 10b5-1 Trading Plan
    6. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
    7. Simbionix Announces License Agreement for Surgical Videos
    8. BioTrends Announces the Continuation of a Syndicated Report Series: TreatmentTrends: CKD Stages 1-5ND
    9. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
    10. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
    11. PDI, Inc. Announces $17 Million Multi-Year Sales Contract
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/1/2014)... 2014 Quantum Materials Corp (OTCQB:QTMM) today ... photoactive quantum dots for use in next-generation ... advantages for solar power generation, the high cost ... dots with which to develop thin film solar ... utilization and acceptance. The company is also seeking ...
    (Date:10/1/2014)... Oct. 1, 2014 Ardelyx, Inc. ... biopharmaceutical company focused on cardio-renal, gastrointestinal and ... its 371 patient Phase 2b clinical trial ... bowel syndrome (IBS-C).  Results from this study ... in IBS-C symptoms for tenapanor-treated patients compared ...
    (Date:10/1/2014)... , October 1, 2014 ... Next Generation Sequencing (NGS) data analysis, today launches a ... cystic fibrosis analysis in a single NGS experiment. The ... all types of variants in a single NGS experiment ... it has not been possible to simultaneously analyse all ...
    Breaking Medicine Technology:Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2
    ... ST. LOUIS, April 21, 2011 / PRNewswire/ ... FDA approved liquid potassium iodide product indicated for thyroid ... has implemented the changes necessary to ramp up production ... ThyroShield is an over-the-counter iodide solution which, ...
    ... Ind., April 21, 2011 Hill-Rom Holdings, Inc., (NYSE: ... a management presentation at Deutsche Bank,s 36th Annual Health ... 2:10 p.m. ET. You are invited to ... at http://ir.hill-rom.com/events.cfm or access it directly at ...
    Cached Medicine Technology:Fleming Pharmaceuticals Now Ready to Step Up Production of Nuclear Radiation Safeguard, ThyroShield® 2
    (Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining how ... , Smoking will always have a negative impact on ... method to find affordable coverage. Insurance brokerage websites specialize ... , Whole life insurance premiums will be fixed throughout ... is permanent, the initial rates are very important. ...
    (Date:10/1/2014)... FARMINGTON, Conn. (PRWEB) October 01, 2014 ... its company, including a redefined mission and visual ... the power of partnering with them to create ... more agile brand that focuses on empowering customers ... benefits communications. , The crown jewel of the ...
    (Date:10/1/2014)... Maine (PRWEB) October 01, 2014 Between ... disorders in the U.S., according to figures from the ... Related Diseases Association (AARDA), and many of them have ... chance of having undiagnosed celiac disease. Gluten Free ... raise awareness of undiagnosed celiac disease by publishing a ...
    (Date:10/1/2014)... (PRWEB) October 01, 2014 Anti Aging ... and skin rejuvenating destination of choice, is announcing a ... October through to December. , “We’re doing this because ... possible to our top skin clinic in Toronto,” says ... do so much at Anti Aging Clinic, including laser ...
    (Date:10/1/2014)... Nordic Naturals is kicking off a ... The campaign—“Buy One Bottle. Help Two Heroes.”—will raise ... nonprofit organization that helps rebuild the lives of ... would otherwise face euthanasia. From October through December ... donations of Nordic Naturals omega-3s to veterans and ...
    Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2
    ... (HealthDay News) -- Telling yourself that an angry person is just ... help take the sting out of their ire, a new study ... angry person is an approach commonly suggested in cognitive behavioral therapy. ... just lost his dog or received bad news and is taking ...
    ... Emergency Department fellow Alyssa Turner, M.D., has been ... presentation at the American Academy of Pediatrics annual ... Blocks in the Pediatric Emergency Department," was deemed ... a physician-in-training. Turner and co-authors Keith ...
    ... , FRIDAY, Nov. 18 (HealthDay News) -- Those in the ... U.S. government health experts now encourage Americans to ... new system assigns no points to nearly all fruits and ... what,s the big deal? Why is it so important to ...
    ... , FRIDAY, Nov. 18 (HealthDay News) -- Women who ... therapy have a 33 percent higher risk of developing breast ... study says. It also found that new-onset breast tenderness ... taking estrogen alone. The findings, based on an analysis ...
    ... , FRIDAY, Nov. 18 (HealthDay News) -- Skilled ... they see them, a new study indicates. Instead, once ... in their brains to recognize it every time they see ... these findings could provide new insight into certain reading disorders. ...
    ... Montreal, November 17, 2011 -- Colleagues who work ... seasonal as the flu. Yet are sick employees workplace troopers ... new study from Concordia University, published in the Journal ... attending work when ill, isn,t always a productive option. ...
    Cached Medicine News:Health News:Think 'It's Not Me, It's You,' When Dealing With Angry Person 2Health News:For Nutritional Punch, You Can't Beat Plant-Based Foods 2Health News:For Nutritional Punch, You Can't Beat Plant-Based Foods 3Health News:For Nutritional Punch, You Can't Beat Plant-Based Foods 4Health News:Tender Breasts From Combo HRT Linked to Higher Cancer Risk 2Health News:Words Recognized by Looks, Not Sounds 2Health News:Presenteeism: A new word for working when sick 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: